WallStSmart

Nuvation Bio Inc (NUVB)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Nuvation Bio Inc generates 19178% more annual revenue ($143.05M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -102.1%. NUVB earns a higher WallStSmart Score of 29/100 (F).

NUVB

Avoid

29

out of 100

Grade: F

Growth: 6.3Profit: 2.5Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: -1.96

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NUVB2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
2599.0%10/10

Revenue surging 2599.0% year-over-year

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.299/10

Conservative balance sheet, low leverage

Areas to Watch

NUVB4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Operating MarginProfitability
4.7%3/10

Operating margin of 4.7%

Return on EquityProfitability
-45.7%2/10

ROE of -45.7% — below average capital efficiency

Altman Z-ScoreHealth
-1.962/10

Distress zone — elevated risk

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : NUVB

The strongest argument for NUVB centers on Revenue Growth, Debt/Equity. Revenue growth of 2599.0% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : NUVB

The primary concerns for NUVB are EPS Growth, Operating Margin, Return on Equity.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

NUVB profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

NUVB carries more volatility with a beta of 1.53 — expect wider price swings.

NUVB is growing revenue faster at 2599.0% — sustainability is the question.

NUVB generates stronger free cash flow (5M), providing more financial flexibility.

Bottom Line

NUVB scores higher overall (29/100 vs 24/100) and 2599.0% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Nuvation Bio Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. The company is headquartered in New York, New York.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?